Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
The 15 Most Motivating TED Discusses All Time- 2026 Golden Globes: How to watch, start time, TV channel, full nominee list and more
- Spots to Go Hang Floating
- Step by step instructions to Guarantee the Life span of Your Dental Inserts: Support and Care Guide
- How Seniors Can Use Refunds and Motivators to Purchase a Hyundai Ioniq EV
- Shredded cheese sold in dozens of states recalled due to potential for metal fragment contamination
- Social Skylines d: A Survey of \Inside and out Social Experiences\ Language Learning Book
- The Starbucks for Life game is back, along with your chance to win a 'Bearista' cold cup. Here's how to get your paws on one.
- How did humans evolve, and will we evolve more?
